Hawk Ridge Capital Management LP Makes New Investment in IQVIA Holdings Inc. $IQV

Key Points

• Hawk Ridge Capital Management LP acquired a new stake in IQVIA Holdings Inc. during Q1, purchasing 437,302 shares valued at approximately $77 million, which now represents 3.6% of their holdings.
• Insider trading reports show that Keriann Cherofsky and Eric Sherbet sold shares of IQVIA, reducing their ownership stakes by 15.87% and 17.59%, respectively.
• IQVIA reported Q2 earnings of $2.81 EPS, surpassing analyst expectations, and the stock has garnered a consensus rating of "Moderate Buy" with an average price target of $229.86.

Hawk Ridge Capital Management LP acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 437,302 shares of the medical research company's stock, valued at approximately $77,096,000. IQVIA accounts for approximately 3.6% of Hawk Ridge Capital Management LP's portfolio, making the stock its 14th biggest position. Hawk Ridge Capital Management LP owned 0.25% of IQVIA as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC lifted its position in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Trading Up 0.0%

IQV traded up $0.04 during mid-day trading on Monday, reaching $187.72. The stock had a trading volume of 1,304,279 shares, compared to its average volume of 1,920,680. The stock has a market capitalization of $31.91 billion, a P/E ratio of 27.17, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm's fifty day simple moving average is $179.88 and its two-hundred day simple moving average is $167.23. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IQV. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Evercore ISI increased their target price on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Robert W. Baird increased their target price on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Finally, Truist Financial increased their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $229.86.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.